NCT06928363View on ClinicalTrials.gov

A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

November 12, 2027

Study Completion Date

December 15, 2027

Conditions
Solid Tumors
Interventions
DRUG

KY-0301

KY-0301 is an antibody-drug conjugate (ADC) targeting both EGFR and c-Met, developed independently by Novatim Immune Therapeutics (Zhejiang) Co., Ltd

Sponsors
All Listed Sponsors
lead

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

INDUSTRY

NCT06928363 - A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter